美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · CLYM近 30 天 3 則 · 第 1 / 1 頁
- Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
- Why Climb Bio, Up 1,300% Over 17 Months, Just Took A Tumble
- Climb Bio (CLYM) Advances Phase 2 Trial In China, Is The Valuation Already Priced In?
- Do Climb Bio’s (CLYM) Mixed Loss Trends Reveal a Shifting Path to Sustainable Scale?
- Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
- Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
- Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
- Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
- Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
- Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
- Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing
- Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。